Q-omics provides the consensus-scored LTB profile across patient tissues and cancer cell-line models. LTB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LTB is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, LTB RNA expression shows 17,712 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KICH, and LSCC as cancer lineages where LTB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LTB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LTB survival associations across molecular data types. LTB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LTB RNA expression–survival associations across cancer types. High LTB expression shows unfavorable associations in UVM, LGG and KIRC, but favorable associations in HNSC, SKCM and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LTB RNA expression.
This table summarizes LTB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LTB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LTB shows lower tumor expression in KICH and COAD and higher tumor expression in KIRC, STAD, BRCA and LIHC. The KICH box plot shows higher LTB RNA expression in normal versus tumor tissue (log2 FC = −1.814, t-test p < 0.001).
This table shows molecular features associated with LTB in patient tissues and cancer cell lines. In patient samples, LTB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LTB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
